Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Outcomes of acute lymphoblastic leukemia (ALL) in older adults treated with chemotherapy are poor. The CD19/CD3 bispecific T-cell engager (BiTE) antibody blinatumomab is approved for refractory, relapsed or minimal/measurable residual disease (MRD)-positive B-cell ALL, but there is little experience...

Descripción completa

Detalles Bibliográficos
Autores principales: Niyongere, Sandrine, Sanchez-Petitto, Gabriela, Masur, Jack, Baer, Maria R., Duong, Vu H., Emadi, Ashkan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7345996/
https://www.ncbi.nlm.nih.gov/pubmed/32560218
http://dx.doi.org/10.3390/ph13060124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7345996/
https://www.ncbi.nlm.nih.gov/pubmed/32560218
http://dx.doi.org/10.3390/ph13060124

Ejemplares similares